NCT01137682 · OUTCOME

Change From Baseline in Mean GH Values for Patients Treated With Pasireotide LAR Alone or With Concomitant Medications Used to Treat Acromegaly for CORE Visits (Extension Full Analysis Set)

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly · Source last updated 2018-04-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: mcg/L
Interval / dispersion: Standard Deviation
Time frame: CORE baseline up to approximately 24 weeks

Analysis population: Number analyzed is based on available data at specific visits

Groups in this outcome

Pasireotide LAR 40 mg

Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days

Pasireotide LAR 60 mg

Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Pasireotide LAR 40 mg	57
Pasireotide LAR 60 mg	54

Reported measurements

Week 12 - CORE

Analysis denominator · Participants

Group	Source count
Pasireotide LAR 40 mg	57
Pasireotide LAR 60 mg	52

Values in mcg/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Pasireotide LAR 40 mg	-0.8	29.77	Not reported	Not reported	Not reported
Pasireotide LAR 60 mg	-6.4	14.35	Not reported	Not reported	Not reported

Week 24 - CORE

Analysis denominator · Participants

Group	Source count
Pasireotide LAR 40 mg	54
Pasireotide LAR 60 mg	48

Values in mcg/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Pasireotide LAR 40 mg	-0.6	32.38	Not reported	Not reported	Not reported
Pasireotide LAR 60 mg	-7.2	15.19	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
29.77
value
-0.8
group Id
OG001
spread
14.35
value
-6.4
denoms
counts
group Id
OG000
value
57
group Id
OG001
value
52
units
Participants
title
Week 12 - CORE
categories
measurements
group Id
OG000
spread
32.38
value
-0.6
group Id
OG001
spread
15.19
value
-7.2
denoms
counts
group Id
OG000
value
54
group Id
OG001
value
48
units
Participants
title
Week 24 - CORE

denoms

counts
group Id
OG000
value
57
group Id
OG001
value
54
units
Participants

dispersion Type

Standard Deviation

groups

description
Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days
id
OG000
title
Pasireotide LAR 40 mg
description
Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days
id
OG001
title
Pasireotide LAR 60 mg

param Type

MEAN

population Description

Number analyzed is based on available data at specific visits

reporting Status

POSTED

time Frame

CORE baseline up to approximately 24 weeks

title

Change From Baseline in Mean GH Values for Patients Treated With Pasireotide LAR Alone or With Concomitant Medications Used to Treat Acromegaly for CORE Visits (Extension Full Analysis Set)

type

SECONDARY

unit Of Measure

mcg/L

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice